EMD Serono clinical trials

Acquired by Merck KGaA, Darmstadt, Germany, Jan 5, 2007 · source ↗

The registry lists 91 studies whose lead sponsor is EMD Serono. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 24, 2022.

Studies

Recruiting first, then most recently updated. Showing 50 of 91. List all 91 → · All Merck KGaA, Darmstadt, Germany studies →

• First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid TumorsCompletedNCT01014936Phase 1

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical TrialsCompletedNCT01013350

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)CompletedNCT00093964Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)TerminatedNCT02070978Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Trial of Pimasertib With SAR245409 or Placebo in Ovarian CancerCompletedNCT01936363Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• First-in-Human Dose Escalation Trial in Subjects With Advanced MalignanciesCompletedNCT01971515Phase 1

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Combination Trial of Pimasertib (MSC1936369B) With TemsirolimusTerminatedNCT01378377Phase 1

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated DyskinesiaCompletedNCT00105508Phase 3

  Sponsor listed in the registry: EMD Serono · First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) PatientsCompletedNCT00082628Phase 3

  Sponsor listed in the registry: EMD Serono · First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory DysfunctionCompletedNCT00213148Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisCompletedNCT00078338Phase 4

  Sponsor listed in the registry: EMD Serono · First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung CancerCompletedNCT00111839Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated DyskinesiaCompletedNCT00105521Phase 3

  Sponsor listed in the registry: EMD Serono · First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Tecemotide (L-BLP25) in Prostate CancerCompletedNCT01496131Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot TrialCompletedNCT01085318Phase 4

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous MelanomaCompletedNCT01693068Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Efficacy and Safety of Atacicept in Systemic Lupus ErythematosusCompletedNCT01972568Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung CancerTerminatedNCT02049151Phase 3

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Trial of Pimasertib in Hematological MalignanciesTerminatedNCT00957580Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.WithdrawnNCT00408967Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Relative Bioavailability of Pimasertib in Cancer PatientsCompletedNCT01992874Phase 1

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Trial of Gemcitabine With or Without MSC1936369B in Pancreatic CancerCompletedNCT01016483Phase 1/2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• MSC2015103B in Solid TumorsTerminatedNCT01453387Phase 1

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Atacicept in Multiple Sclerosis Extension Study, Phase IITerminatedNCT00853762Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Rebif® Rebidose® Versus Rebiject II® Ease-of-UseCompletedNCT02019550Phase 4

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid TumorsCompletedNCT01390818Phase 1

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT01040832Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter StatusCompletedNCT00813943Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl FumarateTerminatedNCT02117050Phase 4

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Sarizotan in Parkinson Patients With L-dopa-induced DyskinesiaCompletedNCT00314288Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany

• A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian CancerCompletedNCT00073541Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany

• A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the KneeTerminatedNCT01689337Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• MSB0010445 and Stereotactic Body Radiation Therapy in Advanced MelanomaTerminatedNCT01973608Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Sym004 in Subjects With Stage IV Non-small Cell Lung CancerTerminatedNCT02083679Phase 1

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)TerminatedNCT01085331Phase 1/2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT01226745Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)TerminatedNCT00642902Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)TerminatedNCT01963611Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus NephritisTerminatedNCT00573157Phase 2/3

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)CompletedNCT00624338Phase 2/3

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Atacicept in Subjects With Optic NeuritisTerminatedNCT00624468Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)CompletedNCT00430495Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)CompletedNCT00595413Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate CancerCompletedNCT01360840Phase 2

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)CompletedNCT00409188Phase 3

  Sponsor listed in the registry: EMD Serono · First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Rebif New Formulation (RNF) in Relapsing Forms of Multiple SclerosisCompletedNCT00110396Phase 3

  Sponsor listed in the registry: EMD Serono · First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Easypod United States User TrialCompletedNCT00689260Phase 4

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)CompletedNCT01207648

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Adherence Trial With MS LifeLines ® ServicesTerminatedNCT01905527

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany

• Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter StatusCompletedNCT00689221Phase 3

  Sponsor listed in the registry: EMD Serono · First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany